Details for New Drug Application (NDA): 214085
✉ Email this page to a colleague
The generic ingredient in DARUNAVIR is darunavir. There are twenty-five drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the darunavir profile page.
Summary for 214085
| Tradename: | DARUNAVIR |
| Applicant: | Zydus Lifesciences |
| Ingredient: | darunavir |
| Patents: | 0 |
Pharmacology for NDA: 214085
| Mechanism of Action | Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inhibitors HIV Protease Inhibitors |
Suppliers and Packaging for NDA: 214085
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DARUNAVIR | darunavir | TABLET;ORAL | 214085 | ANDA | Zydus Lifesciences Limited | 70771-1745 | 70771-1745-5 | 500 TABLET, FILM COATED in 1 BOTTLE (70771-1745-5) |
| DARUNAVIR | darunavir | TABLET;ORAL | 214085 | ANDA | Zydus Lifesciences Limited | 70771-1745 | 70771-1745-6 | 60 TABLET, FILM COATED in 1 BOTTLE (70771-1745-6) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 600MG | ||||
| Approval Date: | Dec 13, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 800MG | ||||
| Approval Date: | Dec 13, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
